Barcelona, Spain. New data presented at the EULAR meeting (European League Against Rheumatism) demonstrate that MabThera's (rituximab) effectiveness in relieving patients of the distressing ...

Washington, U.S. -- Data presented at this year's American College of Rheumatology Congress (ACR) show that patients receiving repeat treatment with MabThera/Rituxan (rituximab) achieved continued ...

The company’s blockbuster oncology drugs are Avastin, Herceptin and MabThera/Rituxan. These three drugs alone accounted for roughly 40% of the company’s overall revenues in 2016. However ...

MabThera shown to be effective and well tolerated over the long-term A study has shown that rheumatoid arthritis patients given multiple courses of MabThera experienced further improvements in ...

NEW YORK Roche will present results of a study of its arthritis medication MabThera at a four-day meeting of the European League Against Rheumatism in Paris that begins Wednesday. The company ...

New Phase III Data Suggest Potential Role for MabThera in Treating Blood Disorder New data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) today, show that people ...

Basel, 15 March 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe ...

Following Herceptin earlier this year, Roche has announced that tampered vials of it's blood cancer drug MabThera (Rituxan) were found in Germany. Swiss drugmaker Roche said on Friday that ...

New hope for patients with most common form of leukaemia in adults Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved MabThera (rituximab) for use in ...

Roche’s cancer and inflammatory diseases drug, MabThera (rituximab), finally faces biosimilar competition in Europe, four years after its patent expired. The Swiss pharma has enjoyed several ...

ZURICH (Reuters) - Roche Holding AG said on Friday its top-selling cancer drug MabThera helped patients with Chronic Lymphocytic Leukaemia (CLL) to live longer without their disease getting worse ...

ZURICH, Jan 23 (Reuters) - European drug regulators have recommended approval for Roche Holding AG's top-selling cancer drug MabThera to treat leukaemia, the Swiss drugmaker said on Friday.